EB613 - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Editorial infographic showing the proposed combination of Panzani and Cerealis, highlighting an indicative €1.8 billion enterprise value, about €1 billion in combined annual revenue, nearly 1,800 employees, a 2025 revenue base of €620 million for Panzani and €400 million for Cerealis, and a European footprint spanning France, Portugal, Spain, the Netherlands and Central Europe.

Panzani and Cerealis plan €1.8bn European food group with €1bn in annual revenue

Mesoblast (ASX: MSB) reports US$99m cash after stronger Ryoncil sales and lower expenditure

Capital Limited (LSE: CAPD) revenue jumps 23% as Fortescue drilling deal expands

Jupiter Fund Management (LSE: JUP) assets hit £75.9bn as investor inflows return

Read More

Pharma Industry News

Entera Bio’s next big opportunity: Can its oral osteoporosis treatment transform a market dominated by injections?

Entera Bio's EB613 osteoporosis results strengthen its Phase 3 outlook. Explore the $275M financing, stock reaction and commercial potential.

bySoujanya Ravi

October 15, 2026

web analytics